Cargando…

Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care

Drug–drug interactions (DDIs) are a leading cause of morbidity and mortality. New tools are needed to improve identification and treatment of DDIs. We conducted a randomized controlled trial to assess the clinical utility of a new test to identify DDIs and improve their management. Primary care phys...

Descripción completa

Detalles Bibliográficos
Autores principales: Peabody, John, Tran, Mary, Paculdo, David, Schrecker, Joshua, Valdenor, Czarlota, Jeter, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262337/
https://www.ncbi.nlm.nih.gov/pubmed/30366371
http://dx.doi.org/10.3390/jcm7110384
_version_ 1783375082444292096
author Peabody, John
Tran, Mary
Paculdo, David
Schrecker, Joshua
Valdenor, Czarlota
Jeter, Elaine
author_facet Peabody, John
Tran, Mary
Paculdo, David
Schrecker, Joshua
Valdenor, Czarlota
Jeter, Elaine
author_sort Peabody, John
collection PubMed
description Drug–drug interactions (DDIs) are a leading cause of morbidity and mortality. New tools are needed to improve identification and treatment of DDIs. We conducted a randomized controlled trial to assess the clinical utility of a new test to identify DDIs and improve their management. Primary care physicians (PCPs) cared for simulated patients presenting with DDI symptoms from commonly prescribed medications and other ingestants. All physicians, in either control or one of two intervention groups, cared for six patients over two rounds of assessment. Intervention physicians were educated on the DDI test and given access to these test reports when caring for their patients in the second round. At baseline, we saw no significant differences in making the DDI diagnosis (p = 0.071) or DDI-related treatment (p = 0.640) between control and intervention arms. By round two, providers who accessed the DDI test performed significantly better in making the DDI diagnosis (+41.6%) and performing DDI-specific treatment (+12.2%) than in the previous round, and were 9.8 and 20.4 times more likely to diagnose and identify the DDI (p < 0.001 for all). The introduction of a definitive DDI test significantly increased identification, appropriate management, and counseling of DDIs among PCPs, which has the potential to improve clinical care.
format Online
Article
Text
id pubmed-6262337
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62623372018-12-03 Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care Peabody, John Tran, Mary Paculdo, David Schrecker, Joshua Valdenor, Czarlota Jeter, Elaine J Clin Med Article Drug–drug interactions (DDIs) are a leading cause of morbidity and mortality. New tools are needed to improve identification and treatment of DDIs. We conducted a randomized controlled trial to assess the clinical utility of a new test to identify DDIs and improve their management. Primary care physicians (PCPs) cared for simulated patients presenting with DDI symptoms from commonly prescribed medications and other ingestants. All physicians, in either control or one of two intervention groups, cared for six patients over two rounds of assessment. Intervention physicians were educated on the DDI test and given access to these test reports when caring for their patients in the second round. At baseline, we saw no significant differences in making the DDI diagnosis (p = 0.071) or DDI-related treatment (p = 0.640) between control and intervention arms. By round two, providers who accessed the DDI test performed significantly better in making the DDI diagnosis (+41.6%) and performing DDI-specific treatment (+12.2%) than in the previous round, and were 9.8 and 20.4 times more likely to diagnose and identify the DDI (p < 0.001 for all). The introduction of a definitive DDI test significantly increased identification, appropriate management, and counseling of DDIs among PCPs, which has the potential to improve clinical care. MDPI 2018-10-25 /pmc/articles/PMC6262337/ /pubmed/30366371 http://dx.doi.org/10.3390/jcm7110384 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peabody, John
Tran, Mary
Paculdo, David
Schrecker, Joshua
Valdenor, Czarlota
Jeter, Elaine
Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title_full Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title_fullStr Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title_full_unstemmed Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title_short Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
title_sort clinical utility of definitive drug–drug interaction testing in primary care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262337/
https://www.ncbi.nlm.nih.gov/pubmed/30366371
http://dx.doi.org/10.3390/jcm7110384
work_keys_str_mv AT peabodyjohn clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare
AT tranmary clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare
AT paculdodavid clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare
AT schreckerjoshua clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare
AT valdenorczarlota clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare
AT jeterelaine clinicalutilityofdefinitivedrugdruginteractiontestinginprimarycare